CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement
CorMedix shares reached a 52-week low after DaVita's CFO indicated that Medicare add-on payments for the DefenCath catheter lock solution are expected to decline significantly starting in the second quarter of 2027.
DaVita Inc. 3rd Quarter 2026 Results
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026:... The post DaVita Inc. 3rd Quarter 2026 Results appeared first on Investor.
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with... The post DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health R
DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice
DaVita today issued the following statement in response to the U.S. Department of Health and Human Services' Kidney Care National Plan and related remarks regarding the future of kidney care:... The post DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and
CorMedix 8-K (7.01, 9.01): Regulation FD disclosure
CorMedix said the FDA accepted for Priority Review its partner Mundipharma’s supplemental application for REZZAYO to prevent invasive fungal disease, setting a target decision date in Q1 2027; if approved, the company aims to begin promotional efforts in the second half of 2027.